Indeed, several studies have tested the efficacy of combination therapy with PARPi and different small molecules, such as antibody-drug conjugates, FLT3 inhibitor, DNMTi, and HDACi, in AML cells. The gene discussed is FLT3; the disease is acute myeloid leukemia.